ProMIS Reports Q2 2026 Results: $53.4M Cash Runway Through 2027, Net Loss Narrows Per Share
PMN has more than doubled off its 52-week low of $6.27 on light trading volume (0.2× avg).
Summary
ProMIS Neurosciences reported Q2 2026 financial results with a net loss of $11.7M and $53.4M in cash, expected to fund operations through 2027. The company also provided pipeline updates and noted four new analyst initiations.
Key Events · Earnings and Guidance · PMN
-
Q2 2026 Net Loss of $11.7M
Net loss was $11.7 million, or $1.28 per share, compared to $10.1 million, or $7.26 per share, in Q2 2025. The per-share improvement reflects higher weighted-average shares outstanding (9.14M vs 1.39M) following the January 2026 private placement.
-
Cash Runway Through 2027
Cash and short-term investments totaled $53.4 million as of June 30, 2026, up from $6.1 million at year-end 2025. Management expects this to fund operations through 2027, beyond the anticipated Q1 2027 topline readout from PRECISE-AD.
-
Pipeline Progress
PMN267 (ALS/FTD) has been humanized and is in IND-enabling studies; PMN442 (PD/DLB/MSA) has been humanized and is advancing toward IND-enabling studies.
-
Analyst Coverage Expansion
Four new research firms initiated coverage during the quarter: Cantor Fitzgerald, Roth Capital, Brookline Capital Markets, and Chardan Capital Markets.
Analysis · PMN · Life Sciences
Second-quarter 2026 results show a net loss of $11.7 million, or $1.28 per share, compared with a loss of $10.1 million, or $7.26 per share, in the year-earlier period. The per-share improvement stems from a significant increase in weighted-average shares outstanding following the January 2026 private placement. With $53.4 million in cash and short-term investments at quarter-end, management expects funding to extend through 2027, beyond the anticipated Q1 2027 topline readout from the PRECISE-AD trial. The filing also details pipeline progress on PMN267 and PMN442 toward IND-enabling studies and notes four new analyst initiations. While the interim trial data was previously announced on July 28, 2026, the financial results and corporate updates represent new material information.
At the time of this filing, PMN was trading at $14.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.6M. The 52-week trading range was $6.27 to $27.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.